title: Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma.
abstract: OBJECTIVE
  Because of the scarcity of information regarding long-term follow-up of pulmonary function after whole-lung irradiation, a prospective study was started at the University of Florida in 1979 to evaluate pulmonary function after treatment with whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma.
  
  
  METHODS
  Between 1979 and 1984, 57 osteogenic sarcoma patients with no evidence of metastatic disease at diagnosis received adjuvant therapy consisting of whole-lung irradiation (with the heart shielded) followed by Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). The whole-lung irradiation schema was 1,600 cGy in 10 fractions with 8-MV x-rays via anterior and posterior fields. This was followed by five cycles of Adriamycin for a total dose of 450 mg/m2. Pulmonary function tests (PFTs) consisting of spirometry, lung volumes, and diffusing capacity were obtained before the whole-lung irradiation, at 6 and 12 months after irradiation, and at yearly intervals thereafter.
  
  
  RESULTS
  At the time of analysis, 28 of the 57 patients were available for study, with a mean follow-up of 42 months (range, 6 to 77 months). Follow-up pulmonary function testing revealed decreased forced vital capacity (FVC) and forced expiratory volume at 1 second (FEV1) during the first 6 to 12 months after whole-lung irradiation. These values returned to baseline during the second-year posttherapy and remained at baseline throughout the remainder of the follow-up period. Changes in lung volumes demonstrated a similar early trend, with significant decreases in total lung capacity (TLC) and functional residual capacity (FRC) at 6 to 12 months. These changes, however, did not improve significantly during the remainder of the follow-up period. Diffusing capacity of the lungs for carbon monoxide (DLCO) also reached a nadir at 6 to 12 months after whole-lung irradiation, with resolution by 2 years and maintenance of at least baseline values for the remainder of the follow-up period.
  
  
  CONCLUSIONS
  Treatment with whole-lung irradiation and Adriamycin, as given in this study, caused no significant sequelae, as demonstrated by pulmonary function testing during the mean follow-up period of 42 months, although a mild, transient restrictive ventilatory defect occurred at 6 to 12 months after treatment.
authors.affiliation: Department of Radiation Oncology, University of Florida College of Medicine, Gainesville 32610-0385.
authors.forename: E R
authors.initials: ER
authors.lastname: Ellis
authors.forename: R B
authors.initials: RB
authors.lastname: Marcus
authors.forename: M J
authors.initials: MJ
authors.lastname: Cicale
authors.forename: D S
authors.initials: DS
authors.lastname: Springfield
authors.forename: F J
authors.initials: FJ
authors.lastname: Bova
authors.forename: J
authors.initials: J
authors.lastname: Graham-Pole
authors.forename: W F
authors.initials: WF
authors.lastname: Enneking
authors.forename: S S
authors.initials: SS
authors.lastname: Spanier
authors.forename: R R
authors.initials: RR
authors.lastname: Million
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology* / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy / Q000532:radiotherapy*; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D012129:Respiratory Function Tests
chemical_list: D004317:Doxorubicin